Harald Seeger
ORCID: 0000-0003-1552-7983
· 5 papers in corpus
article
2012
OBJECTIVES: Dienogest (DNG) is already used in hormone therapy, since recently being also the progestogenic component of the first estradiol based contraceptive pill. Data on breast cancer risk are currently not available. Progesterone rece…
article
2010
Dienogest (DNG) has the essential properties of an effective progestogen for use in a new contraceptive pill using estradiol valerate as estrogenic component -- it inhibits ovulation and protects against endometrial proliferation. DNG is a …
article
2002
ObjectivesChanges in estradiol metabolism may play a role in the pathophysiology of different diseases, of special interest being an increase in D-ring over A-ring metabolites for the risk of breast cancer. In the present work we investigat…
article
2001
ObjectivesAim was to compare the effects of estradiol-only therapy with combined estradiol/progestin treatment on the excretion of vasoactive mediators surrogating on possible effects in the vascular system. The progestin used was dienogest…
article
1996
Mueck, A O M.D., Ph.D.; Graeser, T M.D.2; Mellinger, U Ph.D.2; Mueller, A Ph.D.2; Seeger, H Ph.D.1; Oettel, M M.D.2; Lippert, T H M.D.1 Author Information